Opioid agonist therapy (OAT)

OAT is a highly effective strategy to prevent hepatitis C, HIV, overdose and other drug-related harms. Medication such as methadone is prescribed to reduce or eliminate a person’s use of opioids, depending on their treatment goals.

Resources

Filter By

Filter By

Early findings from safer supply pilot projects

Research summary

CATIE News 02222022

Supervised opioid use combined with housing and other services found to improve health outcomes for people who use drugs

Management of benzodiazepine use

Guideline or manual

Risk mitigation in the context of dual public health emergencies

Guideline or manual

Prescribed safer supply protocols: Fentanyl patch

Access to prescribed safer supply in British Columbia: Policy direction

Guideline or manual

Methadone treatment for people who use fentanyl: Recommendations

Guideline or manual

Opioid agonist therapy: A synthesis of Canadian guidelines for treating opioid use disorder

Research summary

Web research

What is the impact of opioid agonist therapy on hepatitis C testing and treatment for people who inject drugs?

Research summary

Estimated number of people who inject drugs and coverage of harm reduction programs in Canada

Research summary

Improved health when treatment for both hepatitis C and opioid use disorder are offered

Research summary

Research Update

Research Update: Canadian iOAT clinical guideline and operational guidance published